Cynata Therapeutics Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Public

  • Employees
  • 2

Employees

  • Stock Symbol
  • CYP

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $0.15
  • (As of Friday Closing)

Cynata Therapeutics General Information

Description

Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

Contact Information

Website
www.cynata.com
Formerly Known As
EcoQuest
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Level 3, 100 Cubitt Street
  • Cremorne, Victoria 3121
  • Australia
+61 (03)
Primary Industry
Biotechnology
Stock Exchange
ASX
Corporate Office
  • Level 3, 100 Cubitt Street
  • Cremorne, Victoria 3121
  • Australia
+61 (03)

Cynata Therapeutics Timeline

2021202220232024
Financing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cynata Therapeutics Stock Performance

As of 08-Nov-2024, Cynata Therapeutics’s stock price is $0.15. Its current market cap is $26.5M with 181M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.15 $0.14 $0.07 - $0.23 $26.5M 181M 85K

Cynata Therapeutics Financials Summary

As of 30-Sep-2024, Cynata Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2024 FY 2024 30-Jun-2024 FY 2023 30-Jun-2023 FY 2022 30-Jun-2022
EV 19,266 27,633 4,161 19,111
EBITDA (9,647) (3,790)
Net Income (9,598) (3,946)
Total Assets 12,573 18,263
Total Debt 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cynata Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cynata Therapeutics‘s full profile, request access.

Request a free trial

Cynata Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC)
Biotechnology
Cremorne, Australia
2 As of 2008

Paddington, Australia
 

Melbourne, Australia
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cynata Therapeutics Competitors (5)

One of Cynata Therapeutics’s 5 competitors is Cambium Bio, a Corporate Backed or Acquired company based in Paddington, Australia.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cambium Bio Corporate Backed or Acquired Paddington, Australia
Mesoblast Corporation Melbourne, Australia
Athersys Formerly VC-backed Cleveland, OH
Syntara Formerly VC-backed Frenchs Forest, Australia
Pluri Corporation Haifa, Israel
You’re viewing 5 of 5 competitors. Get the full list »

Cynata Therapeutics Patents

Cynata Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019900659-A0 Method Inactive 28-Feb-2019
US-20220119773-A1 Method for improving angiogenic potential of a mesenchymal stem cell Pending 28-Feb-2019
AU-2020227617-A1 Method for improving angiogenic potential of a mesenchymal stem cell Pending 28-Feb-2019
CA-3131395-A1 Method for improving angiogenic potential of a mesenchymal stem cell Pending 28-Feb-2019
EP-3931308-A1 Method for improving angiogenic potential of a mesenchymal stem cell Pending 28-Feb-2019 C12N5/0691
To view Cynata Therapeutics’s complete patent history, request access »

Cynata Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cynata Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cynata Therapeutics‘s full profile, request access.

Request a free trial

Cynata Therapeutics Investments & Acquisitions (3)

Cynata Therapeutics’s most recent deal was a Merger/Acquisition with Cynata. The deal was made on 01-Dec-2013.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cynata 01-Dec-2013 Merger/Acquisition Drug Discovery
Eco Quest 25-Oct-2013 Merger/Acquisition Biotechnology
Cynata 17-Sep-2012 Corporate Drug Discovery
To view Cynata Therapeutics’s complete investments and acquisitions history, request access »

Cynata Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Cynata Therapeutics’s complete esg history, request access »

Cynata Therapeutics FAQs

  • When was Cynata Therapeutics founded?

    Cynata Therapeutics was founded in 2003.

  • Where is Cynata Therapeutics headquartered?

    Cynata Therapeutics is headquartered in Cremorne, Australia.

  • What is the size of Cynata Therapeutics?

    Cynata Therapeutics has 2 total employees.

  • What industry is Cynata Therapeutics in?

    Cynata Therapeutics’s primary industry is Biotechnology.

  • Is Cynata Therapeutics a private or public company?

    Cynata Therapeutics is a Public company.

  • What is Cynata Therapeutics’s stock symbol?

    The ticker symbol for Cynata Therapeutics is CYP.

  • What is the current stock price of Cynata Therapeutics?

    As of 08-Nov-2024 the stock price of Cynata Therapeutics is $0.15.

  • What is the current market cap of Cynata Therapeutics?

    The current market capitalization of Cynata Therapeutics is $26.5M.

  • Who are Cynata Therapeutics’s competitors?

    Cambium Bio, Mesoblast, Athersys, Syntara, and Pluri are competitors of Cynata Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »